



AstraZeneca is committed to **pushing the boundaries of science** to deliver transformative medicines for complex immune-mediated diseases like lupus.

Our **ambition is to move beyond symptom control—targeting clinical remission** and, ultimately, a cure for conditions like SLE, where unmet need remains high.

Many patients still rely on treatments like oral corticosteroids, which can control flares but do not address underlying disease and may lead to irreversible organ damage.¹

By focusing on innovative therapies that reduce reliance on such treatments, we aim to improve long-term outcomes, reduce healthcare costs, and help more patients achieve true remission.

We remain inspired by what science can do as we strive to **transform the lives of people living with immune-mediated diseases.**

**Welcome to hear more at
AstraZeneca's booth!**



1. Fanouriakis A, et al. Changing paradigms in the treatment of systemic lupus erythematosus. *Lupus Science & Medicine*. 2019; 6: